CEL SCI CORP Logo

CEL SCI CORP

Develops immunotherapies for cancer, autoimmune, and infectious diseases.

CVM | US

Overview

Corporate Details

ISIN(s):
US1508377066
LEI:
Country:
United States of America
Address:
8229 BOONE BLVD ., 22182 VIENNA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CEL-SCI Corporation is a clinical-stage biotechnology company specializing in the research and development of immunotherapy products for the treatment of cancer, autoimmune diseases, and infectious diseases. The company's lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a pre-surgical treatment for advanced primary head and neck cancer. Its core therapeutic strategy is to activate the patient's immune system before standard treatments like surgery, chemotherapy, or radiation weaken it. A pivotal Phase III study showed Multikine provided a significant 5-year survival benefit. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) platform for autoimmune and infectious diseases, including a potential treatment for Rheumatoid Arthritis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CEL SCI CORP filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CEL SCI CORP

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CEL SCI CORP via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark
NOVO
NRX Pharmaceuticals, Inc. Logo
Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.
United States of America
NRXP
NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America
NRIX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary
NUTEX
NutriBand Inc. Logo
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America
NTRB
Nuvalent, Inc. Logo
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America
NUVL
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America
NUVB
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565

Talk to a Data Expert

Have a question? We'll get back to you promptly.